When your doctor decides you no longer need daily plasma exchange, you will continue to take CABLIVI for at least 30 days. Treatment with CABLIVI will likely begin in the hospital and continue at home.
You, your family, or your caregiver should receive training from your doctor or nurse until you or they feel confident administering CABLIVI. Let your doctor know if you, your family, or your caregiver are not comfortable doing this or if you have any questions.
The CABLIVI Patient Solutions program is also available to provide additional support and resources as you move from hospital to home.
A. One (1) vial containing CABLIVI, a white powder for solution for injection
B. Two (2) alcohol swabs
C. One (1) syringe containing water to dissolve the powder for injections
D. One (1) sterile vial adapter
E. One (1) sterile needle
There are Instructions For Use that come with CABLIVI, which explain how to administer the medicine. The instructions are also explained in the Administration Training Guide, available in the Support and resources section. It is important that you read through these instructions carefully.
Talk to your doctor before you stop treatment with CABLIVI. Do not stop treatment, even if you start to feel better, as stopping treatment too early could cause you to have another aTTP episode.
When your doctor prescribes CABLIVI, you may receive a welcome kit with your prescription that includes these useful resources:
Please review these materials, and talk to your doctor if you have any questions. If you have not received a CABLIVI Welcome Kit, please contact CABLIVI Patient Solutions at 1-855-724-7222 to sign up.
Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.
Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take.
Talk to your doctor before scheduling any surgery, medical or dental procedure.
CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. Contact your doctor immediately if excessive bleeding or bruising occur.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants.
CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.
CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
TTP=thrombotic thrombocytopenic purpura.